Mangalam Drugs And Organics Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
MANGALAM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Mangalam Drugs and Organics reported weak Q1 FY26 results, swinging to a net loss of Rs 1,372.80 lakhs (standalone) compared to a profit of Rs 268.47 lakhs in the same quarter last year. Revenue from operations dropped to Rs 5,734.87 lakhs from Rs 7,653.62 lakhs, a year-on-year decline of about 25%. Total expenses stood at Rs 6,623.26 lakhs against revenue of Rs 5,734.87 lakhs, leading to an operating loss of Rs 888.39 lakhs versus an operating profit of Rs 432.79 lakhs a year ago. Finance costs remained high at Rs 404.45 lakhs. Consolidated results were similar, with a net loss of Rs 1,379.83 lakhs. The statutory auditor (V.S. Somani & Co.) issued an unmodified limited review report with no qualifications. The board also noted the ongoing merger scheme awaiting NCLT approval, with a creditors and shareholders meeting scheduled for August 12, 2025.
This is a significant negative quarter for shareholders — the company swung from profit to a substantial loss, with revenue contracting sharply and costs outpacing income. Investors should expect short-term pressure on the stock given the swing in profitability and high finance costs relative to operations.